Extensive-Stage Small Cell Lung Cancer and Chemotherapy-Induced Myelosuppression

EP. 1: Chemo-Induced Myelosuppression in ES-SCLC

August 26th 2021

Types of chemotherapy-induced myelosuppression that typically occur in patients with extensive-stage small cell lung cancer and considerations for treating patients based on risk factors and presentation of adverse events.

EP. 2: Clinical Impact of Chemo-Induced Myelosuppression in ES-SCLC

August 26th 2021

Drs Charu Aggarwal and Jared Weiss react to the impact that chemotherapy-induced myelosuppression can have on patients with extensive-stage small cell lung cancer, as well as the overall health system.

EP. 3: Guidelines for Managing Chemo-Induced Myelosuppression in ES-SCLC

September 2nd 2021

Guidance for managing chemotherapy-induced myelosuppressive events in patients with extensive-stage small cell lung cancer based on risk stratification criteria, available therapies, and prophylaxis options.

EP. 4: Limitations When Managing Chemo-Induced Myelosuppression

September 2nd 2021

Pros and cons of strategies used to manage chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer.

EP. 5: Myelopreservation With CDK4/6 Inhibitors

September 9th 2021

The rationale for using CDK4/6 inhibitors to prevent myelosuppression in patients receiving chemotherapy-containing regimens for extensive-stage small cell lung cancer.

EP. 6: ES-SCLC: Trilaciclib for Chemo-Induced Myelosuppression

September 9th 2021

Jared Weiss, MD, of UNC Lineberger Comprehensive Cancer Center, highlights clinical trial data that led to the approval of trilaciclib in patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

EP. 7: Trilaciclib: Treatment Considerations

September 16th 2021

Advantages associated with the administration of trilaciclib in appropriate patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

EP. 8: Expanded Access to Trilaciclib for Patients With ES-SCLC

September 16th 2021

Jared Weiss, MD, reacts to new measures that increase patient access and provider reimbursement to trilaciclib for patients with extensive-stage small cell lung cancer.

EP. 9: Next Steps in Managing Chemo-Induced Myelosuppression

September 16th 2021

Trials of interest exploring various novel therapies as chemoprotection in patients with solid tumor cancers.